Propanc Biopharma Updates on Pancreatic Cancer Research

Propanc Biopharma announced the latest update on pancreatic cancer research. Pancreatic cancer remains one of the most lethal human malignancies: median survival after diagnosis is typically measured in months, and the five-year survival rate is below 10%. Traditional therapies such as surgery, chemotherapy and radiation often fail to achieve durable remission, especially in metastatic or chemoresistant disease. This high unmet need has drawn interest to novel mechanisms of action - including Propanc Biopharma's pancreatic proenzyme formulation known as PRP.Propanc's lead clinical candidate, PRP, is a proprietary mixture of two pancreatic proenzymes - trypsinogen and chymotrypsinogen - formulated in a synergistic 1:6 ratio and administered intravenously. These proenzymes are hypothesized to target cancer stem cells and modulate malignant cellular programs such as the epithelial to mesenchymal transition, a process linked to metastasis and drug resistance. Key Mechanistic Findings from Preclinical Studies include: Suppression of metastatic processes: PRP reduced angiogenesis and cell migration in pancreatic cancer models and appeared to reverse EMT markers that contribute to invasiveness. Enhanced chemosensitivity: Laboratory data suggest PRP makes resistant pancreatic tumor cells more responsive to standard chemotherapies and alters the tumor microenvironment - including reduced fibrosis and dampened TGF-beta pathway signaling. Tumor growth inhibition: In vivo studies in animal models showed significant reduction in pancreatic tumor weight, with greater than85 % growth inhibition at certain PRP doses versus controls. Importantly, the U.S. Food and Drug Administration granted Orphan Drug Designation to PRP in 2017 for the treatment of pancreatic cancer, recognizing the severe unmet need and small patient population. Propanc has progressed its PRP candidate toward human studies. Following an initial public offering and Nasdaq listing, the company is advancing plans to initiate Phase I/II clinical trials in 2026, starting with dose-finding studies and moving to proof-of-concept studies in pancreatic and other cancers.